ROS1基因在非小细胞肺癌靶向治疗中的研究进展
| 作者: |
1郑姣云,
1李代强
1 中南大学湘雅二医院病理科，长沙 410011 |
| 通讯: |
李代强
Email: lidqxf@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2014.06.035 |
摘要
肺癌是最常见的恶性肿瘤之一，ROS1基因是新近发现的出现在非小细胞肺癌(non-small cell lung cancer，NSCLC)中的原癌基因，它编码的蛋白是受体络氨酸激酶超家族成员之一，是一种对细胞 生长和生存起着重要作用的蛋白。越来越多的研究表明，ROS1基因的改变是NSCLC个体化治疗的 一个新的分子靶点。本文将重点综述ROS1的重排在NSCLC的特点、ROS1基因重排的检测方法， 以及NSCLC中以ROS1重排基因作为药物靶点的研究进展。
关键词：
ROS1融合基因
非小细胞肺癌
分子靶向治疗
克唑替尼
Research progress in ROS1 gene in non-small cell lung cancer
CorrespondingAuthor: LI Daiqiang Email: lidqxf@163.com
DOI: 10.3978/j.issn.2095-6959.2014.06.035
Abstract
Lung cancer is one of the most common malignant cancers. ROS1 is an oncogene which is newly found in non-small cell lung cancer (NSCLC). The protein encoded by ROS1 is a member of receptor tyrosine kinase superfamily, and it plays a vital role in cell growth and cell survival. More and more studies demonstrated that the alteration of ROS1 would be a new molecular target for individualized treatment of NSCLC. This review focus on the feature of ROS1 rearrangements in NSCLC, the detection methods of ROS1 rearrangement, and the research progress about taking ROS1 rearrangement as drug target in NSCLC.